ALLOVECTIN Trademark

Trademark Overview

On Wednesday, July 25, 2001, a trademark application was filed for ALLOVECTIN with the United States Patent and Trademark Office. The USPTO has given the ALLOVECTIN trademark a serial number of 76290249. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, August 21, 2015. This trademark is owned by Vical Incorporated. The ALLOVECTIN trademark is filed in the Pharmaceutical Products category with the following description:

Immunotherapeutic pharmaceuticals for the treatment of human malignancy
allovectin

General Information

Serial Number76290249
Word MarkALLOVECTIN
Filing DateWednesday, July 25, 2001
Status710 - CANCELLED - SECTION 8
Status DateFriday, August 21, 2015
Registration Number2919311
Registration DateTuesday, January 18, 2005
Mark Drawing1000 - Typeset: Word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, November 27, 2001

Trademark Statements

Goods and ServicesImmunotherapeutic pharmaceuticals for the treatment of human malignancy

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, August 21, 2015
Primary Code005
First Use Anywhere DateWednesday, October 13, 2004
First Use In Commerce DateWednesday, October 13, 2004

Trademark Owner History

Party NameVical Incorporated
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92121
Party NameVical Incorporated
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92121
Party NameVical Incorporated
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92121

Trademark Events

Event DateEvent Description
Friday, August 21, 2015CANCELLED SEC. 8 (10-YR)/EXPIRED SECTION 9
Tuesday, January 25, 2011REGISTERED - SEC. 8 (6-YR) ACCEPTED
Wednesday, January 19, 2011REGISTERED - SEC. 8 (6-YR) FILED
Wednesday, January 19, 2011TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
Saturday, December 18, 2010POST REGISTRATION ACTION MAILED - SEC. 8
Saturday, December 18, 2010CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Wednesday, November 24, 2010TEAS SECTION 8 RECEIVED
Monday, February 23, 2009ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, February 23, 2009TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, January 18, 2005REGISTERED-PRINCIPAL REGISTER
Tuesday, November 16, 2004LAW OFFICE REGISTRATION REVIEW COMPLETED
Monday, November 15, 2004ASSIGNED TO LIE
Monday, November 8, 2004ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Friday, November 5, 2004STATEMENT OF USE PROCESSING COMPLETE
Monday, October 25, 2004USE AMENDMENT FILED
Monday, October 25, 2004TEAS STATEMENT OF USE RECEIVED
Friday, August 6, 2004EXTENSION 5 GRANTED
Wednesday, July 14, 2004EXTENSION 5 FILED
Monday, July 19, 2004CASE FILE IN TICRS
Wednesday, July 14, 2004TEAS EXTENSION RECEIVED
Monday, April 26, 2004ASSIGNED TO EXAMINER
Thursday, February 5, 2004EXTENSION 4 GRANTED
Wednesday, January 14, 2004EXTENSION 4 FILED
Wednesday, January 14, 2004TEAS EXTENSION RECEIVED
Wednesday, August 27, 2003EXTENSION 3 GRANTED
Thursday, August 14, 2003EXTENSION 3 FILED
Thursday, August 14, 2003TEAS EXTENSION RECEIVED
Friday, May 23, 2003EXTENSION 2 GRANTED
Wednesday, January 22, 2003EXTENSION 2 FILED
Wednesday, January 22, 2003PAPER RECEIVED
Thursday, August 15, 2002EXTENSION 1 GRANTED
Friday, July 19, 2002EXTENSION 1 FILED
Monday, July 22, 2002PAPER RECEIVED
Tuesday, February 19, 2002NOA MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, November 27, 2001PUBLISHED FOR OPPOSITION
Wednesday, November 7, 2001NOTICE OF PUBLICATION
Wednesday, September 19, 2001APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, September 5, 2001ASSIGNED TO EXAMINER

Related Keywords

allovectin malignancy human treatment pharmaceuticals immunotherapeutic